|
Main | | | | |
| Brand Name | Seroquel, XR | | |
| Indication | schizophrenia, bipolar disorder | | |
| Mechanism | atypical antipsychotic | | |
| Safety | Less EPS side effects relative to class, more favorable weight gain vs Zyprexa but equal to Risperdal. | | |
| Price | 7% increase 1/2006 | | |
| Competition | Zyprexa, Abilify, Risperidone/Invega | | |
| Follow-on | Seroquel SR will be qd dosing, effect as early as Day 2 and with faster titration. | | |
| IP | September 2011 expiry. Pediatric extension applicable. | | |
| | June 4 2008 summary judgment hearing with Teva? August 20 2008 30-month stay expiry. Summary judgment granted and no inequitable conduct found. | | |
| | Anchen filed P4 in March 2010. | | |
| | Sues Osmotica and Torrent 8/2010. | | |
| Clinical Studies | BOLDER I and BOLDER II bipolar studies (n=1045). PDUFA 10/30. | | |
| | MDD, GAD | | |
| | | | |
| | Seroquel SR data at ECP. | | |
| | | | |
| | | | |
| Rx | | TRx | NRx |
| | 6/1/2007 | 287913 | 141565 |
| | 5/25/2007 | 297841 | 152431 |
| | 6/1/2006 | 264850 | 130220 |